US drugs developer is latest to move onto science hub
CAMPUS IS NOW THE HOME TO FOUR BLUE-CHIP ORGANISATIONS
CONTRACT drug developer and manufacturer Kindeva Drug Delivery is expanding its operations at the Charnwood Campus life sciences hub in Loughborough.
The US-headquartered company is taking over a state-of-the-art research and development facility on the science park, and a further 20,000sq ft of office space.
Formerly 3M Drug Delivery Systems, Kindeva works on behalf of big pharmaceutical and biotechnology customers and employs more than 500 staff across two UK sites – on the Charnwood Campus, and at a plant in Clitheroe, Lancashire.
The company formulates, develops, and manufactures drugs used by patients suffering from serious health conditions including respiratory illnesses, central nervous system disorders, and cancer.
The Loughborough expansion will provide room for its continued growth in the UK.
Aaron Mann, Kindeva Drug Delivery chief executive, said: “As a growing CDMO (contract development and manufacturing organisations) and life sciences company, Kindeva thrives on our base of well-trained, highly-qualified leaders in scientific research and development.
“The campus provides a state-of-theart laboratory design to support our industry-leading talent. Importantly, the proximity to general management offices promotes cross-functional collaboration between our R&D (research and development) team and other areas of the business, enabling consistent feedback of customer needs and insights into our R&D activities.”
Charnwood Campus is now home to four blue-chip organisations – Almac, 3M, Kindeva and global diagnostics company PerkinElmer.
Charnwood Campus commercial director Gosia Khrais said: “Kindeva’s expansion is great news for both the Charnwood site and the local area, with the company’s ambitious growth plans set to create new office-based roles as well as safeguard hundreds of highly valuable scientific jobs in Loughborough and the East Midlands.
“The deal is another significant milestone in our long-term development plan and further reinforces the East Midlands’ and Loughborough’s reputation for outstanding pharmaceutical research and development.
“With a strong legacy of more than 60 years of pharmaceutical innovation, Kindeva is a well-established business and a significant player in the global drug development and delivery pharmaceutical industry.
“We feel honoured the company has chosen to expand its operations at Charnwood as well as support us in playing our part in the UK’s economic recovery.”
Charnwood Borough Council leader Jonathan Morgan said: “This is excellent news for Charnwood Campus and the borough. I am delighted that not only are a significant number of jobs being safeguarded, but more are being created which is important as we look to the recovery from the pandemic.
“One of the council’s top priorities is to support the growth of the local economy and sites like Charnwood Campus will play a key role in that growth.”
Charnwood Campus is the first Life Sciences Opportunity Zone in the UK and part of the Loughborough and Leicester Science and Innovation Enterprise Zone.